Anti-M. tuberculosis Polyclonal antibody

An adult sheep housed indoors developed chronic respiratory tract infection that was unresponsive to treatment and resulted in euthanasia. Granulomas were found in multiple organs and lymph nodes, which contained acid-fast bacilli identified in Ziehl-Neelsen stains, and Mycobacterium bovis was cultured from tissues, confirming tuberculosis. Tuberculin skin testing of other animals in the building subsequently identified another sheep as infected, which had been housed with the index case for 46 months, although no visible lesions were seen postmortem. A steer that shared common air space with the sheep in the same building was also identified as test reactor and M bovis was cultured from the retropharyngeal lymph node. Strain typing of the isolates from the index case and the steer revealed the same genotype, suggestive of transmission from sheep to steer. This is the first documented episode of M bovis transmission from sheep to cattle.

A cytochrome P450 3A4 (CYP3A4) based enzymatic biosensor was developed with the incorporation of a first-generation copper polypropyleneimine (CuPPI) metallodendrimer for the detection of anti-tuberculosis (anti-TB) drugs. The development of an electrochemical phenotype biosensor for this purpose is still vital since it aids in the ongoing fight against TB by determining metabolic profile. This allows TB treatment to be tailored on an individual patient basis, minimise adverse drug reactions and improve quality of life in TB patients. This simple biosensor was constructed via physical adsorption of CuPPI onto a gold electrode with subsequent electrostatic attachment of CYP3A4. The biosensor was successful in detecting all four first line anti-TB drugs i. e. isoniazid, ethambutol, pyrazinamide and rifampicin with limits of detection ranging from 0.02244 to 0.1072 nM in 0.1 M phosphate buffer. The developed biosensor was then applied towards "real samples" in the form of spiked synthetic urine and plasma. Calibration curves were carried out in the complex matrices, which were diluted with 0.1 M PB. These yielded good LOD in the range of ultra-low micromolar concentration i. e. 0.165-0.884 mu M across all drugs. Recovery studies were also successful when detecting the real tablets in both plasma and urine with results ranging from 91.5 % to 108.5 %.